Nancy Wang, MD
Enriched profileNeuro-oncologist · Massachusetts General Hospital
Nancy Wang is Neuro-oncologist at Massachusetts General Hospital. ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 13 Nov 2026
Overview
Updated 17 Nov 2026
Nancy Wang, M.D., is Neuro-oncologist at Massachusetts General Hospital. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 2 companies.
- Top research focus: Neoplasm Metastasis
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Nov 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Niraparib in Tumors Metastatic to the CNS
Sponsor: Massachusetts General Hospital
- Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Sponsor: Massachusetts General Hospital
- Palbociclib and Pembrolizumab In Central Nervous System Metastases
Sponsor: Massachusetts General Hospital
Industry payments
Updated 13 Nov 2026
2 companies reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- Telix PharmaceuticalsProgram year20252 payments
- Merck Sharp & Dohme LLCProgram year20241 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Other antiepileptics57.7%Levetiracetam100%Part D≥12 patientsGabapentinoids42.3%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 13 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.30911
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →acsjournals.onlinelibrary.wiley.com ↗ - Other
health.usnews.com/doctors/nancy-wang-759229
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Other
pmc.ncbi.nlm.nih.gov/articles/PMC12979032
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗ - Other
tlcr.amegroups.org/article/view/72041/html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
MPH
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Meigs, MD
Massachusetts General Hospital
Keith Flaherty, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Andrew Zhu, MD
Massachusetts General Hospital
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington